Board of Directors
An experienced team with a wealth of experience that provides direction for our organization.
The members of the Fidelis Animal Health board bring expertise in diverse areas of the pharmaceutical industry to help us best serve the animal health community with high-quality innovative solutions.
Meet Our Board of Directors:
BARRY LEVINSON, PhD
Always having an entrepreneurial spirit, Dr. Levinson began his corporate years at the biotech start-up Ecogen. From there, he spent a decade in increasingly senior positions in cardiovascular research and business development for Berlex Labs. He then worked at two consulting firms before joining Aton.
After earning his BA with highest honors in biochemistry from Princeton, Barry went on to earn his MS and PhD degrees in molecular biophysics and biochemistry from Yale University. Mr. Wells also brings eight years of sales and marketing experience with the leading pharmaceutical manufacturer Merck to his roles at Fidelis. After his time at Merck, his first start-up venture was founding Lathian Systems Inc. to provide online data and marketing services to pharmaceutical and biotechnology companies. In addition to serving on the Fidelis Board of Directors and as a University of Pittsburgh Trustee, Mr. Wells currently holds board positions with Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He earned BS and MS degrees from the University of Pittsburgh and an MBA from The Wharton School.
Mr. Midler holds an MBA from Harvard University and MA and BA degrees in political science from Stanford University.
As an accomplished life sciences entrepreneur, Mr. Steadman has founded multiple companies including two in animal health, Exubrion Therapeutics (board chair) and Velcera Pharmaceuticals (CEO). Exubrion has developed and markets a unique canine osteoarthritis treatment, and Mr. Steadman led Velcera from conception and capital funding through to acquisition by a NYSE-traded strategic player.
Mr. Steadman also brings insights from his experience in leading pharmaceutical companies to his board position at Fidelis. He is former vice president (North American) for Merial Animal Health and successfully built the Australasia region and led the US business at Merck Animal Health.
With a BS in business management and an MS in agricultural economics from The Pennsylvania State University, Mr. Steadman also holds a certificate in executive finance from Harvard Business School.
We’re committed to leading the industry with quality-driven therapeutics.